NO20022221L - En fremgangsmåte til en kjemisk forhindring av prostatakreft - Google Patents

En fremgangsmåte til en kjemisk forhindring av prostatakreft

Info

Publication number
NO20022221L
NO20022221L NO20022221A NO20022221A NO20022221L NO 20022221 L NO20022221 L NO 20022221L NO 20022221 A NO20022221 A NO 20022221A NO 20022221 A NO20022221 A NO 20022221A NO 20022221 L NO20022221 L NO 20022221L
Authority
NO
Norway
Prior art keywords
prostate cancer
procedure
chemical prevention
prevents
chemopreventive agent
Prior art date
Application number
NO20022221A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022221D0 (no
Inventor
Mitchell S Steiner
Sharan Raghow
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Publication of NO20022221D0 publication Critical patent/NO20022221D0/no
Publication of NO20022221L publication Critical patent/NO20022221L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20022221A 1999-11-08 2002-05-08 En fremgangsmåte til en kjemisk forhindring av prostatakreft NO20022221L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43620899A 1999-11-08 1999-11-08
US09/531,472 US6413533B1 (en) 1998-05-07 2000-03-20 Method for chemoprevention of prostate cancer
PCT/US2000/030658 WO2001034117A1 (en) 1999-11-08 2000-11-08 A method for chemoprevention of prostate cancer

Publications (2)

Publication Number Publication Date
NO20022221D0 NO20022221D0 (no) 2002-05-08
NO20022221L true NO20022221L (no) 2002-06-28

Family

ID=27030854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022221A NO20022221L (no) 1999-11-08 2002-05-08 En fremgangsmåte til en kjemisk forhindring av prostatakreft

Country Status (20)

Country Link
US (1) US6413533B1 (ko)
EP (1) EP1229903A4 (ko)
JP (1) JP2003513903A (ko)
KR (2) KR100793721B1 (ko)
CN (1) CN1331463C (ko)
AU (1) AU782444B2 (ko)
BG (1) BG65794B1 (ko)
CA (1) CA2390295C (ko)
CZ (1) CZ20021763A3 (ko)
HK (1) HK1057000A1 (ko)
HR (1) HRP20020422A2 (ko)
HU (1) HUP0203304A3 (ko)
IL (1) IL149545A0 (ko)
IS (1) IS6375A (ko)
MX (1) MXPA02004676A (ko)
NO (1) NO20022221L (ko)
PL (1) PL354726A1 (ko)
SK (1) SK8162002A3 (ko)
WO (1) WO2001034117A1 (ko)
YU (1) YU43002A (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
CA2777199A1 (en) 2001-07-09 2003-01-23 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
BR0214801A (pt) 2001-11-29 2005-01-11 Gtx Inc Prevenção e tratamento de osteoporose induzida pela privação de andrógeno
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
KR20030061474A (ko) * 2002-01-14 2003-07-22 한미약품 주식회사 서트랄린 제조용 중간체로서 사용되는 시스-라세메이트화합물의 개선된 제조방법
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005050563A2 (en) * 2003-11-17 2005-06-02 Aureon Biosciences Corporation Pathological tissue mapping
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
EP1728210A2 (en) * 2004-02-27 2006-12-06 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
EP2392322A3 (en) 2005-03-22 2012-02-22 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2007135547A2 (en) * 2006-05-22 2007-11-29 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
WO2009040824A2 (en) * 2007-09-24 2009-04-02 Ganga Raju Gokaraju Anti-adipogenic compositions containing piper betel and dolichos bifloras
CA2702710C (en) 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
PT2616078T (pt) 2010-09-16 2020-03-31 Shimoda Biotech Pty Ltd Composições de fulvestrant e métodos de uso
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2889770A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
JP3566741B2 (ja) * 1992-10-27 2004-09-15 日本化薬株式会社 自己免疫疾患治療薬
DE69329802T2 (de) * 1992-12-01 2001-07-19 Biotie Therapies Corp Syndecan-stimulierung der zellulären differenzierung
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
RU2153332C2 (ru) 1993-08-09 2000-07-27 Орион Корпорейшн Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
EP1019057B1 (en) * 1997-08-15 2008-10-15 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
GB9805868D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
JP4482229B2 (ja) * 1998-05-07 2010-06-16 ユニバーシティ オブ テネシー リサーチ ファウンデーション 前立腺癌の化学防御方法
AU6291699A (en) * 1998-10-06 2000-04-26 Kgk Synergize Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin

Also Published As

Publication number Publication date
HUP0203304A3 (en) 2006-02-28
BG106738A (en) 2003-02-28
WO2001034117A9 (en) 2002-05-10
SK8162002A3 (en) 2003-03-04
KR100793721B1 (ko) 2008-01-10
BG65794B1 (bg) 2009-12-31
WO2001034117A1 (en) 2001-05-17
NO20022221D0 (no) 2002-05-08
CN1420765A (zh) 2003-05-28
KR20020070276A (ko) 2002-09-05
US6413533B1 (en) 2002-07-02
CZ20021763A3 (cs) 2003-02-12
AU1588401A (en) 2001-06-06
HK1057000A1 (en) 2004-03-12
CA2390295A1 (en) 2001-05-17
KR20060130788A (ko) 2006-12-19
CA2390295C (en) 2009-09-29
MXPA02004676A (es) 2004-09-10
CN1331463C (zh) 2007-08-15
JP2003513903A (ja) 2003-04-15
YU43002A (sh) 2005-09-19
HUP0203304A2 (hu) 2003-02-28
EP1229903A4 (en) 2006-06-07
IS6375A (is) 2002-05-08
AU782444B2 (en) 2005-07-28
IL149545A0 (en) 2002-11-10
HRP20020422A2 (en) 2004-04-30
EP1229903A1 (en) 2002-08-14
PL354726A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
NO20022221L (no) En fremgangsmåte til en kjemisk forhindring av prostatakreft
NO20045429L (no) Kombinasjon av organiske forbindelser
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20081042L (no) PPAR aktive forbindelser
NO20080150L (no) Inhibitorer av AKT-aktivitet
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
MX366328B (es) (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilami noisoindolin-1,3-diona: metodos de uso y composiciones de la misma.
CY1107174T1 (el) Συνδυασμοι εζετιμιβε με ασπιρινη για θεραπεια αγγειακων καταστασεων
DK1624878T3 (da) Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
BR0013767A (pt) Aminoalcoxicarbazóis para tratamento de doenças do snc
CA2323809A1 (en) A method for chemoprevention of prostate cancer
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
MA26975A1 (fr) 2-azetinones substituees par des sucres utilisees comme agents hypocholesterolemiants
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
NO20051168L (no) Anvendelse av fermentert hvetekimekstrakt som anti-inflammasjonsmiddel
CL2015001086A1 (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
ATE443044T1 (de) Tace inhibitoren
WO2003024405A3 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
BR0308601A (pt) inibidores de carboxipeptidase b de plasma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application